Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases.

eosinophil-associated diseases patient rights public awareness

Journal

Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158

Informations de publication

Date de publication:
17 May 2023
Historique:
medline: 17 5 2023
pubmed: 17 5 2023
entrez: 17 5 2023
Statut: aheadofprint

Résumé

Eosinophil-associated diseases (EADs) are a group of conditions in which eosinophils (a type of white blood cell) are thought to play a key role in the disease and how it develops. Some EADs are common, such as atopic dermatitis (also called eczema) and a subtype of asthma called eosinophilic asthma, while others are rare, such as hypereosinophilic syndrome (a condition in which a person has a very high number of eosinophils in both the blood and one or more organs). People with EADs face many problems related to their conditions. Symptoms such as severe abdominal pain, itch, or shortness of breath impact both the patient as well as their friends and family. Patients with EADs also experience delays to diagnosis and treatment as well as financial barriers. Healthcare professionals sometimes fail to recognize the complex set of symptoms that characterize an EAD, and this may cause delays in reaching a correct diagnosis. As a result, it may take longer for a patient to get the best care and the most effective treatments, which may contribute to poor health. The goal of this charter is to describe the key elements of good quality care, which all people with EADs deserve, as well as to present an action plan to improve health and overall well-being for people with EADs.

Identifiants

pubmed: 37194573
doi: 10.2217/imt-2022-0312
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

David J Jackson (D)

Guy's Severe Asthma Centre, Guy's & St Thomas' NHS Trust, London, UK.
School of Immunology & Microbial Sciences, King's College, London, UK.

Praveen Akuthota (P)

Division of Pulmonary, Critical Care, & Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Rebeca Andradas (R)

Spanish Association of Eosinophilic Esophagitis-AEDESEO, Madrid, Spain.

Albert J Bredenoord (A)

Department of Gastroenterology & Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.

Amanda Cordell (A)

EOS Network Eosinophilic Diseases Charity, Colchester, England, UK.

Sarah Gray (S)

AusEE Inc., Queensland, Australia.

Joyce Kullman (J)

Vasculitis Foundation, Kansas City, MO, USA.

Sameer K Mathur (SK)

Division of Allergy, Pulmonary & Critical Care Medicine, Department of Medicine, School of Medicine & Public Health, University of Wisconsin, Madison, WI, USA.

Ian Pavord (I)

Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Florence Roufosse (F)

Department of Internal Medicine, Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium.

Christian Rubio (C)

Global Genes, Boston, MA, USA.

Irena Clisson Rusek (IC)

Association Pour l'Information sur les Maladiesa Eosinophiles-APIMEO, Bourg-la-Reine, France.

Dagmar Simon (D)

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Mary Jo Strobel (MJ)

American Partnership for Eosinophilic Disorders, Atlanta, GA, USA.

Tonya Winders (T)

Allergy & Asthma Network, Vienna, VA, USA.
Global Allergy & Airways Patient Platform, Vienna, Austria.

Classifications MeSH